VANCOUVER, BC, April 12, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced it has held a pre-investigational new drug application (PIND) meeting with the United States Food and Drug Administration (FDA) Division of Psychiatry (The Division). During the course of the…


Previous articleNuminus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research
Next articleMindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium